[144] Astera Labs, Inc. SEC Filing

Rhea-AI Filing Summary

Astera Labs (ALAB) submitted a Form 144 notifying the market of a proposed sale of 170,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $30,974,000 and an approximate sale date of 09/02/2025. The shares were acquired in a private issuance from the issuer on 03/21/2018 and were paid for in cash. The filing shows total shares outstanding of 166,219,140, and discloses multiple recent Rule 10b5-1 sales by related trusts between 06/20/2025 and 07/21/2025, with individual gross proceeds listed for each transaction. The signer certifies no undisclosed material adverse information and references reliance on planned trading instructions where applicable.

Insights

Securities Analyst

TL;DR: Routine insider disclosure of a planned sale; absolute proceeds sizable but represent a small fraction of outstanding shares.

The Form 144 is a standard disclosure that notifies the market of a proposed sale by an affiliate or insider. The proposed block of 170,000 shares equals about 0.10% of outstanding shares (170,000 of 166,219,140), so while the dollar value (~$31.0 million) is notable in absolute terms, it is not obviously dilutive or control-changing. The filing also documents recent Rule 10b5-1 executions by related trusts, indicating prearranged trading activity rather than opportunistic sales tied to undisclosed information. For investors, this is transparency on insider liquidity rather than a signal of material operational issues.

Corporate Governance Expert

TL;DR: Proper procedural disclosure with Rule 10b5-1 activity; no explicit governance red flags in the filing.

The document includes the required certifications and lists the broker, acquisition date, and payment method, consistent with compliance expectations for Rule 144 filings. Multiple 10b5-1 sales shown for affiliated trusts suggest ongoing, preplanned dispositions which typically reduce concerns about insider trading tied to undisclosed events. The filer affirms no material nonpublic information is known. The filing does not disclose any new governance changes, litigation, or other corporate actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	170000	30974000.00	166219140	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/21/2018	Private Acquisition from Issuer or an Affiliate	Issuer			170000	03/21/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	07/21/2025	13259	1471749.00
10b5-1 Sales for CASA ALAMEDA 2007, LLC 2345 North First Street San Jose CA 95131	Common	07/03/2025	1991	181432.07
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	07/03/2025	29000	2642656.90
10b5-1 Sales for MAR 2011 CHILDRENS TRUST U/A DTD 06/01/2011 2345 North First Street San Jose CA 95131	Common	07/03/2025	29722	2708449.94
10b5-1 Sales for CASA ALAMEDA 2007, LLC 2345 North First Street San Jose CA 95131	Common	07/02/2025	12000	1079386.80
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	07/02/2025	51000	4587393.90
10b5-1 Sales for MAR 2011 CHILDRENS TRUST U/A DTD 06/01/2011 2345 North First Street San Jose CA 95131	Common	07/02/2025	58000	5217036.20
10b5-1 Sales for CASA ALAMEDA 2007, LLC 2345 North First Street San Jose CA 95131	Common	06/20/2025	3709	374002.21
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	06/20/2025	16441	1657851.25
10b5-1 Sales for MAR 2011 CHILDRENS TRUST U/A DTD 06/01/2011 2345 North First Street San Jose CA 95131	Common	06/20/2025	21978	2216182.40

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Astera Labs' (ALAB) Form 144 disclose?

The filing discloses a proposed sale of 170,000 common shares via Morgan Stanley, with an aggregate market value of $30,974,000 and an approximate sale date of 09/02/2025.

When and how were the shares to be sold in ALAB's Form 144 acquired?

The shares were acquired on 03/21/2018 in a private acquisition from the issuer and paid for in cash.

How large is the proposed sale relative to ALAB's outstanding shares?

The proposed 170,000 shares compare to 166,219,140 shares outstanding, roughly 0.10% of the outstanding share count.

Does the filing show recent insider selling activity for ALAB?

Yes; the filing lists multiple Rule 10b5-1 sales by affiliated trusts between 06/20/2025 and 07/21/2025, with gross proceeds disclosed for each sale.

Does the filer state any undisclosed material information?

The signer represents by the filing that they do not know any material adverse information about the issuer that has not been publicly disclosed.